Impressum Privacy policy

Contact us

+49 3641 508 180

info@inflarx.de

Address

InflaRx N.V.

Winzerlaer Str. 2, 07745 Jena

09-2023-InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
Home Investors Press Releases 09-2023-InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904